Steroid showdown: oral vs. injected for rare eye disease
NCT ID NCT07405489
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 30 people with Vogt-Koyanagi-Harada (VKH) disease, a rare autoimmune condition that causes eye inflammation and can lead to vision loss. Researchers compared two initial treatments: oral prednisolone (steroid pills) and steroid injections near the eye. They checked how well each controlled inflammation at 3 months and tracked vision changes and side effects over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral prednisolone and posterior sub-Tenon triamcinolone acetonide (steroid injections near the eye)
- What this could lead to
- If one approach works better, it could point toward a safer, more effective first treatment for VKH eye inflammation, potentially reducing the need for systemic steroids.
- What could go wrong
- This is a small, retrospective study with only 30 participants, so results may not apply to everyone. It compares two existing treatments, not a new breakthrough, and cannot prove which is definitively better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VKH SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Benha University
Banhā, Benha, 13111, Egypt